gesunheitpfleges.org



New biomarker-based test more effective for early acute kidney injury detection

March 26, 2016

Helping lead the international multi-center study were, Michael Haase, M.D., Department of Nephrology and Hypertension and Endocrinology and Metabolic Diseases, Otto-von-Guericke-University, Magdeburg, Germany; Anja Haase-Fielitz, PharmD., Department of Nephrology and Intensive Care, Charite-University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany; and Rinaldo Bellomo, M.D., Department of Intensive Care, Austin Hospital, Melbourne, Australia.

"Our findings suggest an important analogy between the troponin/creatine kinase relationship in acute myocardial infarction and the NGAL/creatinine relationship in AKI for the identification of previously undetected organ injury," said Dr. Bellomo, director of Intensive Care Research at Austin Hospital, and senior author of this study. "Just as the increased diagnostic sensitivity of troponin has dramatically altered the definition, diagnosis, and management of acute myocardial infarction, similar concepts might apply to NGAL and AKI."

The researchers now plan to pursue a prospective multi-center study to further verify the effectiveness of the NGAL test as a prognostic biomarker in a large population of patients in critical care settings.

Patents and intellectual property rights for the use of NGAL for earlier acute kidney injury diagnosis are jointly owned by Cincinnati Children's and Columbia University in New York, N.Y. The technology has been exclusively licensed to industry (Abbott Diagnostics, Biosite, Inc.) for clinical development and commercialization. Standardized clinical laboratory tests for detecting urine and blood NGAL are being used globally and currently under evaluation by the U.S. Food and Drug Administration for use in the United States.

Source: Cincinnati Children's Hospital Medical Center